Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study

Press Release

Vancouver, British Columbia, April 28, 2025 – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that it will host a virtual R&D Day on Tuesday, May…

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research

Press Release

— Dennis Dlugos, MD, MSCE; Jacqueline French, MD; Terrence O’Brien, MD; Jo Sourbron, MD, PhD, MPharm; and Joseph Sullivan, MD, bring decades of experience in epilepsy drug developmentand research to support Company’s clinical focus on epilepsy —   Vancouver, British Columbia, March 4,2025 – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ: DRUG) (“Bright Minds” or the…

Bright Minds Biosciences to Participate at Three Healthcare Conferences in March

Press Release

New York and Vancouver, BC – February 24, 2025 – Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Ian McDonald, Chief Executive Officer, and…

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

Uncategorized

— Dr. Collins brings extensive drug development and clinical expertise in epilepsy —   New York and Vancouver, BC – January 07, 2025 – Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other…